Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Simoens

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacy and Therapeutics|April 21, 2015
What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analysesE Picavet, D Cassiman, S Simoens
Human Reproduction Update|June 23, 2007
Endometriosis: cost estimates and methodological perspectiveS Simoens, L Hummelshoj, T D'Hooghe
The Journal of Hospital Infection|July 9, 2005
Follow-up of antibiotic prophylaxis: impact on compliance with guidelines and financial outcomesL Willems, S Simoens, G Laekeman
Journal of Clinical Pharmacy and Therapeutics|February 24, 2010
Medication information for Flemish inpatients with major depression: evaluation and construct validity of the Consumer Information Rating FormF Desplenter, G Laekeman, K Demyttenaere, et al.
International Journal of Antimicrobial Agents|June 21, 2005
Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance developmentS Simoens, J Verhaegen, G Laekeman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 25, 2005
Promoting targeted screening for Type 2 diabetes mellitus: the contribution of community pharmacistsS Simoens, E Foulon, M Dethier, et al.
Journal of Clinical Pharmacy and Therapeutics|June 27, 2012
Market uptake of orphan drugs--a European analysisE Picavet, L Annemans, I Cleemput, et al.
Public Health|April 30, 2024
Cost-utility analysis of expanding the colorectal cancer screening policy in FlandersM Lelie, R Parmentier, S Simoens, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 17, 2017
The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventionsJ Schepers, J Plaete, I De Bourdeaudhuij, et al.
Pharmacoepidemiology and Drug Safety|September 16, 2011
Drug use among persons with Type 2 diabetes mellitus prior to diagnosis in BelgiumS Simoens, S De Coster, J Lenie, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacy and Therapeutics|April 21, 2015
What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analysesE Picavet, D Cassiman, S Simoens
Human Reproduction Update|June 23, 2007
Endometriosis: cost estimates and methodological perspectiveS Simoens, L Hummelshoj, T D'Hooghe
The Journal of Hospital Infection|July 9, 2005
Follow-up of antibiotic prophylaxis: impact on compliance with guidelines and financial outcomesL Willems, S Simoens, G Laekeman
Journal of Clinical Pharmacy and Therapeutics|February 24, 2010
Medication information for Flemish inpatients with major depression: evaluation and construct validity of the Consumer Information Rating FormF Desplenter, G Laekeman, K Demyttenaere, et al.
International Journal of Antimicrobial Agents|June 21, 2005
Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance developmentS Simoens, J Verhaegen, G Laekeman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 25, 2005
Promoting targeted screening for Type 2 diabetes mellitus: the contribution of community pharmacistsS Simoens, E Foulon, M Dethier, et al.
Journal of Clinical Pharmacy and Therapeutics|June 27, 2012
Market uptake of orphan drugs--a European analysisE Picavet, L Annemans, I Cleemput, et al.
Public Health|April 30, 2024
Cost-utility analysis of expanding the colorectal cancer screening policy in FlandersM Lelie, R Parmentier, S Simoens, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 17, 2017
The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventionsJ Schepers, J Plaete, I De Bourdeaudhuij, et al.
Pharmacoepidemiology and Drug Safety|September 16, 2011
Drug use among persons with Type 2 diabetes mellitus prior to diagnosis in BelgiumS Simoens, S De Coster, J Lenie, et al.
Pageof 3